Skip to main content

Top Left Menu

  • Careers
  • Media
  • Investors
  • Library

What are you looking for?

Home

You are here

Galderma Global

Choose another location

  • Argentina
  • Australia
  • Austria
  • Belgium
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Czech Republic
  • Denmark
  • Finland
  • France
  • Germany
  • Hong Kong/Macau SAR, China
  • India
  • Italy
  • Japan
  • Kingdom of Saudi Arabia
  • Korea
  • Mainland China
  • Mexico
  • Middle East
  • Netherlands
  • Nordic
  • Norway
  • Poland
  • Portugal
  • Russia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan, China
  • Thailand
  • United Kingdom
  • United States
  • Venezuela

Top menu

  • Contact us
  • Search

Main navigation

  • About us
    • At a glance
    • Our purpose
    • Our strategy
    • Our sub-categories
    • Global presence
    • Executive Committee
    • Governance
    • Annual Report 2025
  • Skin Stories
    • Galderma skin stories
    • Skin Science
    • Beauty x Medicine
    • Galderma Insights
    • Podcasts
  • Innovation
    • Bringing innovation to life
    • Partnerships
    • Manufacturing
    • Early Access
  • Our brands
  • Sustainability
    • For our employees
    • For patients and consumers
    • For healthcare professionals and customers
    • Governance oversight
    • Funding request for education and support activities
    • Our ESG Index
  • Media
  • Careers
  • Investors
You searched for: «【✈️ Telegram ID: KPU77】 대성피 성인 피시방 안전 보장 100% 알거래 중개소 리스트 - 용인»
Results 111 - 115 of 155
Page 23 of 31
  1. Media
  2. Newsroom

Galderma announces new data demonstrating the positive anti-inflammatory effect and mode of action of nemolizumab in patients with moderate to severe Prurigo Nodularis

Results from transcriptomic (RNA Gene Expression) data now published in the Journal of Allergy and Clinical Immunology:

  1. Media
  2. Newsroom

Galderma Demonstrates Robust Aesthetic Innovation Pipeline with Initiation of Seven New Clinical Studies

In Addition, Ten Data Releases Will Be Presented at the American Society for Dermatologic Surgery (ASDS) Annual Meeting

  1. Media
  2. Newsroom

Galderma Launches TWYNEO® Cream, the First Ever Tretinoin and Benzoyl Peroxide Combination to Treat Facial Acne

TWYNEO (tretinoin and benzoyl peroxide) Cream, 0.1%/3% unveiled at American Academy of Dermatology Annual Meeting and commercially available in spring

  1. Media
  2. Newsroom

Galderma online survey reveals almost two thirds of rosacea patients* are experiencing worsening of signs and symptoms related to essential COVID-19 mask wearing

  • Although essential for public health, new online survey findings show that people with self-reported rosacea* may be experiencing worsening of symptoms due to mask wearing, further increasing the daily burden for people living with this chronic skin disease
  • Despite worsening of signs and symptoms, only a third (33%) of respondents have visited a healthcare provider (HCP)
  1. Media
  2. Newsroom

Galderma to unveil ground-breaking data from across its leading dermatology portfolio and showcase major update for sensitive skincare brand CETAPHIL® at the 2021 EADV Congress

  • Galderma will host six symposia and three industry hubs, and present several scientific posters demonstrating its expertise and its commitment to advancing dermatology
  • The company will unveil exciting new data relating to rosacea, acne, actinic keratosis, atopic dermatitis, pediatric atopic dermatitis, prurigo nodularis, onychomycosis, sensitive skin and maskne
  • Nemoli
Results 111 - 115 of 155
Page 23 of 31

Pagination

  • Previous page Previous Page
  • Next page Next Page
  1. Home
  2. Search results

STAY CONNECTED

Follow us on Social Media for current news and patients stories

Instagram LinkedIn Icon Twitter Icon
© Galderma 2026

Footer menu 2

  • Terms of use
  • Cookie Policy
  • Privacy
  • Sitemap

Confirm navigation

You are about to leave the Galderma global site. Are you sure you want to leave this page?

Yes, thanks Go back